Relationship of myocardial remodeling to the genesis of serum autoantibodies to cardiac beta1-adrenoceptors and muscarinic type 2 acetylcholine receptors in rats  by Liu, Hui-Rong et al.
Relationship of Myocardial Remodeling
to the Genesis of Serum Autoantibodies to
Cardiac Beta1-Adrenoceptors and
Muscarinic Type 2 Acetylcholine Receptors in Rats
Hui-Rong Liu, MD, PHD,* Rong-Rui Zhao, MD, PHD,* Xiang-Ying Jiao, MD, PHD,*
Ying-Yuan Wang, MD, PHD,* Michael Fu, MD, PHD†
Taiyuan, China and Go¨teborg, Sweden
OBJECTIVES We sought to investigate the mechanism responsible for the occurrence of anticardiac
receptor autoantibodies.
BACKGROUND Increasing evidence suggests the involvement of autoimmune mechanisms in the pathogenesis
of a number of cardiovascular diseases. Among them, the biologic, functional and pathogenic
properties of anticardiac receptor antibodies have been extensively investigated. However, the
mechanism responsible for the occurrence of anticardiac receptor autoantibodies remains
poorly understood.
METHODS Two rat models (aortic banding [AB] and adriamycin [ADR] groups) were constructed.
Determination of cardiac function and morphology and T-lymphocyte subtypes, enzyme-
linked immunosorbent assay and cardiomyocyte cultures were performed.
RESULTS It was shown, in the AB and ADR groups, that the frequency and titer of autoantibodies to
beta1 and muscarinic type 2 receptors were increased when myocardial remodeling occurred,
as evidenced by significant cardiac morphologic changes, deposition of collagen and obvious
functional impairment. This suggests that cardiac remodeling itself, in two disparate models
of heart failure and cardiomyopathy, was able to trigger the genesis of anticardiac receptor
autoantibodies. These autoantibodies have biologic effects similar to those seen in human
autoantibodies. They have also shown a characteristic self-growth, as well as a time-course
decline, suggesting that a negative finding of anticardiac receptor autoantibodies in sera of
patients with heart disease does not necessarily imply that there is no autoimmune reaction
involved in the pathogenesis.
CONCLUSIONS Our results demonstrated that myocardial damage was able to trigger the occurrence of an
autoimmune reaction, resulting in the genesis of anticardiac receptor autoantibodies with
properties similar to those seen in patients with idiopathic dilated cardiomyopathy. (J Am
Coll Cardiol 2002;39:1866–73) © 2002 by the American College of Cardiology Foundation
In recent years, autoantibodies to cardiac beta1-
adrenoceptors and muscarinic type 2 (M2) acetylcholine
receptors have been found in the sera of patients with
dilated cardiomyopathy (DCM) (1–3). Matsui et al. (3)
have confirmed the presence of autoantibodies against a
series of G-protein–coupled cardiovascular receptors in
patients with DCM and found that circulating antireceptor
autoantibodies in these patients were mainly confined to
two functionally predominant cardiac receptors—beta1-
adrenoceptors and M2 receptors—rather than other G-
protein–coupled receptors. Further studies have shown that
these antireceptor autoantibodies are functionally active
(1–5), suggesting the involvement of these autoantibodies in
the pathogenesis of DCM. However, apart from DCM,
autoantibodies to cardiac beta1-adrenoceptors and M2 re-
ceptors have also been found in Chagas’ heart disease,
rheumatic heart disease, hypertensive cardiomyopathy and
myocardial infarction associated with heart failure (6–10).
These findings suggest that the anticardiac receptor auto-
antibodies are not restricted to patients with DCM, but can
also be found in some other cardiac diseases associated with
obvious cardiac structural and functional changes. Little
information, however, is available regarding the mechanism
for the genesis of autoantibodies to cardiac receptors in the
course heart diseases. A clarification of the relationship
between the myocardial pathologic state and the genesis of
antireceptor autoantibodies may deepen our understanding
of the role of the autoimmune mechanism in the pathogen-
esis of heart diseases.
We have extended the previous studies in this field to
answer the following questions. 1) How is the myocardial
remodeling process during the development of heart failure
related to the genesis of autoantibodies to cardiac beta1-
adrenoceptors and M2 receptors? To answer this question,
we first set up two experimental animal models that had
undergone myocardial remodeling, and then we determined
their serum antireceptor autoantibodies before and after the
experiment. 2) What are the biologic and pharmacologic
properties of the autoantibodies generated, if any, in relation
to the myocardial remodeling process? To answer this
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question, we determined the functional role of the immu-
noreactive autoantibodies to cardiac receptors generated in
such a way.
METHODS
Animal models. Healthy 12-week-old Wistar rats of either
gender, with normal blood pressure and heart rate, weighing
200 to 240 g, were selected for this study. Animals were
classified randomly into two experimental groups, with
respective control groups (n 24 in each group), as follows:
1) the aortic banding (AB) group, in which the abdominal
aorta was banded according to the methods of Doering et al.
(11). In the sham-operated control group, the animals were
treated with the same surgical procedure, except for AB. 2)
The adriamycin (ADR) (doxorubicin) group, in which
ADR at 1.0 mg/kg body weight per week was administered
through the sublingual vein (12). In its corresponding
control group, a same volume of normal saline replaced
adriamycin. Throughout the experiment, 1 ml of blood
sample was taken from all groups through the caudal vein
before and 1, 2, 4, 6, 8, 10,12 and 14 weeks after treatment.
The sera were separated and stored at 70°C until use. At
2, 8 and 14 weeks after treatment, four animals each time
were anesthetized with 40 mg/kg sodium pentobarbital
intraperitoneally, and left ventricular (LV) function was
measured invasively. The heart was then excised and frozen
in liquid nitrogen and stored at 70°C until use.
Measurement of in vivo cardiac function. After anesthe-
sia, a cannula was inserted into the LV to measure the
following primary and derived variables: heart rate, LV
systolic pressure, LV end-diastolic pressure and the maximal
rate of rise and/or decline in LV pressure (dP/dtmax).
After completion of the measurements, the blotted weight
of the whole heart was weighed. A mid-LV section (about
2 mm in thickness) perpendicular to the major axis of the
heart was made and fixed in 10% formalin.
Cardiac anatomic measurements. The wall thickness,
cavity dimension, cavity area and total ventricular wall area
were measured at the mid-sections of each heart after
sectioning and staining with hematoxylin-eosin. The mea-
surements were made using a computerized image analysis
system (MIANS-300, Sichuan, China). The total ventric-
ular wall area included the ventricular area, interventricular
septum, trabeculae carnae and papillary muscles attached to
the wall.
Inspection of cardiac structure. The cardiac structure was
examined by routine light microscopy. The myocardial
ultrastructure was inspected by transmission electron mi-
croscopy. For this purpose, small pieces of heart tissue were
fixed with 2.5% glutaraldehyde in 0.1 mol/l phosphate
buffer (pH 7.4) for 2 h at 4°C. They were washed with
phosphate buffer and then post-fixed with 1% osmium
tetroxide for 2 h at 4°C. After dehydration with a graded
series of dehydrating acetone, the specimens were infiltrated
with epoxy 618. Ultra-thin sections (50 nmol/l in thickness)
were cut using the LKB ultra-microtome IV after polymer-
ization at 60°C, stained with a solution of uranyl acetate and
lead citrate, and observed under a 100-CX transmission
electron microscope.
Myocardial collagen staining and image processing. The
histologic section of ventricular tissue was stained with van
Gieson’s solution of trinitrophenol and acid fuchsin (a kind
of collagen staining) for microscopic inspection and image
processing. Six microscopic fields per section were sampled.
The percentage of collagen tissue per field was calculated,
and the final average was adopted as the percent collagen
volume fraction (CVF).
Enzyme-linked immunosorbent assay (ELISA). Peptides
corresponding to the sequence of the second extracellular
loops of human beta1-adrenoceptors and M2 receptors were
synthesized, and ELISA was performed as previously de-
scribed (2–4).
Determination of CD3, CD4 and CD8 T cells. For
measurement of CD3, CD4 and CD8 T lymphocytes
in the rat’s peripheral blood, preparation of samples and
determination by flow cytometry (FACScan, Becton Dick-
inson and Co., Mountain View, California), as well as
analysis with the Cellquest Software on an Apple Power
Macintosh, were carried out as described by Lyons and
Parish (13). The following monoclonal antibodies were used
for combining T lymphocyte: fluorescein isothiocyanate
(FITC)-labeled anti-rat CD3, FITC-labeled rat CD4 and
phycoerythrin-labeled rat CD8 (Pharmingen Co., San Di-
ego, California).
Binding characteristics of beta1-adrenoceptors and M2
receptors. Tissue preparation was done using the methods
reported by Vandermolen et al. (14). Normal sections of rat
cardiac tissue were used as the source of both receptors for
radioligand binding. Ventricular tissues were trimmed to a
dimension of 5  5 mm and embedded in OCT (Miles).
The tissue sections were consecutively cut to 16 mol/l in
thickness on a cryostat (18°C) microtome (Ryocut 1800).
One of five consecutive sections, which formed a set, was
used to measure tissue protein by the routine method.
Iodine-125-pindolol and 3H-quinuclidinyl benzylate were
Abbreviations and Acronyms
AB  aortic banding
ADR  adriamycin
Bmax  maximal number of receptor binding
sites
CD4/CD8  ratio of helper to suppressor peripheral
blood T lymphocytes
CVF  collagen volume fraction
DCM  dilated cardiomyopathy
dP/dtmax  maximal rate of rise and/or decline in
left ventricular pressure
ELISA  enzyme-linked immunosorbent assay
FITC  fluorescein isothiocyanate
LV  left ventricle/ventricular
Kd  dissociation constant
M2  muscarinic type 2
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used as radioligands for the beta1-adrenoceptor and M2
receptor, respectively. The binding assay was carried out by
binding the specific ligands directly to the frozen slide
tissues. Saturation-binding isotherms were obtained by
incubating the sections for 1 h with varying concentrations
of either iodine-125-pindolol or 3H-quinuclidinyl benzy-
late. The saturation-binding variables of the maximal num-
ber of binding sites (Bmax) and the dissociation constant
(Kd) were determined using the Prism 2.01 program. The
activities of the positive sera against beta1-adrenoceptors
and M2 receptors were observed after pre-incubation of
these sera with heart tissue sections for 60 min at 37°C,
before binding studies were performed.
Culture of neonatal, beating cardiomyocytes. The hearts
were removed aseptically from one- to two-day-old Wistar
rats and cultured as previously described (5). The number of
beats of a selected isolated myocardial cell or a cluster of
synchronously contracting cells in each of 10 fields was
counted for 15 s each time. The rat serum, synthetic antigen
peptide and corresponding receptor agonists were added,
and the cells were observed 5 min after each addition. This
procedure was repeated twice in different cultures to yield
results representing a total of 30 cells or cell clusters. The
basal heart rate was 140  20 beats/min.
Statistical analysis. Results are expressed as the mean
value  SD. The average of the antibody titer was ex-
pressed as the geometric mean value. The normality of the
geometric mean value of antibody titer was tested using the
D test (applicable for a sample size of 50 to 1,000). A
comparison among groups was done using analysis of
variance with SPSS version 10.0 software (SPSS Inc.,
Chicago, Illinois). Values of p  0.05 were considered as
significant.
RESULTS
Changes in heart weight to body weight ratio. Two
weeks after treatment, the heart weight to body weight ratio
increased significantly in the AB group, whereas no obvious
changes were observed in the ADR group. Eight weeks after
treatment, however, in both groups, the heart weight to
body weight ratio was considerably increased, as compared
with that of each control group. Fourteen weeks after
treatment, the heart weight to body weight ratio in both
groups tended to decrease, as compared with that at eight
weeks after treatment, but it was still significantly different
from that in each control group by term, as shown in
Table 1. In both experimental animal models, the gross
pathologic changes characteristic of congestive heart failure,
including excessive hydrocardia and ascites, an enlarged,
pale kidney and cardamom liver with central tubule necrosis,
were observed at 14 weeks after treatment.
Cardiac function. As shown in Table 2, there were no
significant changes in LV function for both groups after
two weeks of treatment. Eight weeks after treatment,
however, the LV systolic and diastolic functions, expressed
by dP/dtmax and dP/dtmax, as well as other variables
(data not shown), were remarkably decreased in both
groups, compared with the control group. Fourteen weeks
after treatment, the variables of systolic function showed no
further decreasing tendency, whereas the variables of dia-
stolic function, such as dP/dtmax, were even more de-
creased than those at the preceding time point.
Cardiac anatomic measurements. Longitudinal sections
of the hearts from the ADR group, at the end of the
experiment, showed dilation of both the left and right
ventricles, with wall thickening. The hearts from the AB
group, upon death within 12 weeks of the initial operation,
were conspicuously large in size and showed markedly
thickened LVs, whereas the hearts from the control group
showed a normal chamber size and wall thickness (Table 3).
Light and electron microscopic findings. In both groups,
the morphologic examinations of the hearts, by light and
electron microscopy, displayed a significant remodeling
process, as shown by myocyte hypertrophy, elongation,
multifocal degeneration and necrosis, focal myofibrillar lysis,
hypercontraction banding of myofibrils, mitochondrial vac-
uolation and condensation. No histologic changes were
found in the hearts of the two control groups.
Table 1. Change in Heart/Body Weight Ratio (mg/g) in Wistar
Rats Treated With AB or ADR After 2, 8 and 14 Weeks (n  8)
Week
Sham
Operation AB Saline ADR
2 2.15  0.09 3.35  0.15* 2.18  0.10 2.25  0.12
8 2.25  0.11 4.08  0.23† 2.29  0.12 4.04  0.20‡
14 2.22  0.12 3.73  0.30* 2.23  0.15 3.74  0.18§
*p  0.05, †p  0.01 versus sham-operated control group. ‡p  0.01, §p  0.05
versus saline control group. Data are presented as the mean value  SD.
AB  aortic banding; ADR  adriamycin.
Table 2. Left Ventricular Function, Expressed as dP/dtmax (kPa/s), in Each Group at
Different Times (n  6)
Post
Treatment
Week
Control Group* AB Group ADR Group
dP/dtmax dP/dtmax dP/dtmax dP/dtmax dP/dtmax dP/dtmax
2 359.8  27.3 239.8  10.1 317.2  30.9 256.2  15.2 362.9  28.1 227.9  13.2
8 367.6  29.8 228.1  12.4 202.4  39.0† 176.1  28.4† 210.3  32.6‡ 167.4  18.6†
14 340.8  27.2 223.7  12.2 213.0  40.3 130.6  30.4† 212.7  33.0† 127.5  26.3†
*Including both the sham-operated group and saline group. †p  0.05, ‡p  0.01 versus the corresponding control group. Data
are presented as the mean value  SD.
Abbreviations as in Table 1.
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Myocardial collagen network remodeling. In both exper-
imental groups, the LV CVF percentages were all consid-
erably higher than those in the corresponding control
groups after 8 and 14 weeks, as shown in Table 4. Micro-
scopically, a lot of collagen deposition could be seen around
the myocardial small vessels in both experimental models at
two weeks after treatment. Deposition of collagen became
more prominent and was accompanied by increased tissue
space and collagenous fibers at eight weeks after treatment.
Furthermore, a thickened collagen compartment appeared
around the small vessels, and a more extensive and severe
deposition of collagen was observed in between the myo-
cardial fibers after 14 weeks of treatment.
Changes in the T lymphocyte subpopulation. The in-
crease in the CD4/CD8 ratio denotes the enhancement
of positive immunoregulatory function and, hence, pro-
motes the production of antibody. As shown in Table 5, the
ratios of CD4/CD8 increased remarkably after 2 and 8
weeks in the AB, as compared with pretreatment, but were
normalized after 14 weeks. In the ADR group, there were
changes similar to those in the AB group at 2 and 8 weeks,
but the ratio of CD4/CD8 still remained at a high level
at 14 weeks after treatment.
Detection of serum autoantibodies to beta1-adrenoceptor
and M2 receptor before and after treatment. In both
experimental groups, the frequency of occurrence and titer
of autoantibodies to beta1-adrenoceptor and M2 receptors in
the sera before treatment were at a very low level. However,
these were remarkably increased in both experimental
groups after four weeks of treatment (Fig. 1). Moreover, the
serum levels varied as a function of time (Fig. 2).
Effects of autoantibodies on ligand binding to the corre-
sponding receptor. In both the AB and ADR groups with
positive sera for the beta1-adrenoceptor, the normal Bmax
value of 35.1  8.2 fmol/mg was decreased to 17.1 
9.1 fmol/mg and 18.2  7.4 fmol/mg (both p  0.01),
respectively, although the Kd was not significantly changed.
Similarly, both groups with positive sera for the M2 receptor
had a decrease in Bmax from the normal value of 71.3 
10.5 fmol/mg to 36.4  9.8 fmol/mg and 34.2 
7.3 fmol/mg (both p  0.01), respectively, and an increase
in the Kd from the normal value of 3.80  0.37 nmol to
6.70  0.22 nmol and 7.10  0.20 nmol (both p  0.01),
respectively. The effects of positive sera (autoantibodies)
were dose-dependent, reaching a maximal decrease in Bmax
of 50%. The inhibitory effects of autoantibodies in both
experimental groups were abolished by incubating the pos-
itive sera for both receptors with anti-rat immunoglobulin
G monoclonal antibody.
Chronotropic effect on cultured cardiomyocytes. The
positive sera for the beta1-adrenoceptor from both experi-
mental groups were able to increase the heart beat fre-
quency, in the same way as the effect of the beta1-
adrenoceptor agonist isoprenaline. This effect of the anti–
beta1-adrenoceptor autoantibody in positive sera was
abolished by the addition of the beta1-adrenoceptor antag-
onist propranolol, or by pre-incubating the sera with the
corresponding antigenic peptide. In contrast, the positive
sera for the M2 receptor from both experimental groups
were able to decrease the heart beat frequency, in the same
way as the effect of the muscarinic agonist carbachol.
Likewise, the addition of the muscarinic antagonist atropine
and the corresponding antigenic peptide could abolish this
effect (Fig. 3).
DISCUSSION
Myocardial damage triggered the genesis of autoanti-
body. In this study, we definitely demonstrated that myo-
cardial damage itself, in two disparate models of heart
failure and cardiomyopathy, was able to trigger the occur-
rence of an autoimmune reaction, resulting in the genesis of
anticardiac receptor autoantibodies in the absence of any
additional interfering factors. In connection with the afore-
mentioned clinical observations (1–10), although our results
with rats may have some species-related difference, they
could lend support to the view that the occurrence of
abnormal anticardiac receptor antibodies is not restricted to
Table 4. Collagen Volume Fraction (%) of the Left Ventricle in
Both the Aortic Banding and Adriamycin Groups (n  8)
Week
Sham
Operation AB Saline ADR
2 7.16  0.81 9.03  0.92* 7.76  0.96 8.64  1.05
8 8.20  1.28 11.63  2.48† 8.15  0.98 12.98  2.84†
16 8.64  0.50 13.70  2.12† 8.49  0.61 13.70  2.43†
*p  0.05, †p  0.01 versus the corresponding control group. Data are presented as
the mean value  SD.
CVF  fraction of collagen volume; other abbreviations as in Table 1.
Table 5. Changes in the Ratio of CD4/CD8 Before and
After Treatment in Both the AB and ADR Groups (n  8)
Post-
Treatment
Week
Sham
Operation AB Saline ADR
0 1.89  0.40 1.92  0.43 1.94  0.34 1.98  0.38
2 1.95  0.36 2.86  0.24* 2.04  0.43 2.99  0.25*
8 1.93  0.43 3.26  0.24† 2.01  0.38 3.49  0.41†
14 1.92  0.46 1.99  0.51 1.95  0.46 2.56  0.39*
*p  0.05, †p  0.01 versus pretreatment. Data are presented as the mean value 
SD.
CD4/CD8  ratio of helper T cells to suppressive T cells; other abbreviations
as in Table 1.
Table 3. Anatomic Measurements of Hearts (mm2) From Each
Group at the End of the Experiment
Group
Control*
(n  8)
AB
(n  6)
ADR
(n  6)
Cavity area (RV) 1.58  0.23 4.08  0.43† 4.89  0.86‡
Cavity area (LV) 5.46  0.44 11.38  1.65 15.11  1.86†
Total ventricular
wall area
31.30  2.76 62.95  8.88 81.94  13.55†
*Including both the sham-operated group and saline group. †p  0.05, ‡p  0.01
versus control group. Data are presented as the mean value  SD.
LV  left ventricle; RV  right ventricle; other abbreviations as in Table 1.
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DCM, but can also occur in relation to cardiac pathologic
changes due to some other heart diseases. In support of our
experimental findings, Peukert et al. (15) reported the
occurrence of anticardiac receptor autoantibodies and their
correlation with a clinical manifestation in patients with
hypertrophic cardiomyopathy.
Biologic property of generated autoantibodies. In both
experimental models of this study, it was shown that the
Figure 1. Changes in the frequency of the occurrence of both autoantibodies in the sera, before (pre) and after (post) four weeks of treatment. AB  aortic
banding group (n  24); ADR  adriamycin group (n  24); Control  control of both experimental groups (n  48). **p  0.01 versus control group.
Figure 2. Time course of genesis of both autoantibodies in terms of changes in titers of autoantibodies after aortic banding (AB) (A) and adriamycin (ADR)
(B) treatment (only sera positive for autoantibodies are shown).
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autoantibodies induced by the cardiac remodeling process
have pharmacologic and physiologic effects similar to those
seen in human autoantibodies and rabbit antipeptide anti-
bodies. These suggest that the autoantibodies generated due
to cardiac structural and functional changes possess a
biologic function similar to that in patients with DCM and,
thus, can contribute to exacerbation of cardiac pathologic
changes and dysfunction. Although beta1-adrenoceptor and
M2 receptor antibodies have the opposite functional effects,
it is difficult to judge the overall effect on cardiac function,
because the effects of antibodies are dependent not only on
their concentrations, but also on their affinities and avidities
in antigen-antibody interactions. For example, the concen-
tration of autoantibodies needed to affect the beta1-
adrenoceptor is pharmacologically 10 times weaker than
that needed to affect the M2 receptors (3). It is currently
Figure 3. Chronotropic effects on cultured neonatal rat cardiomyocytes induced by sera positive for the beta1-adrenoceptor (A) or the M2 receptor (B).
These effects were respectively abolished by the addition of both receptor antagonists and pre-incubation with both antigenic peptides. PS  positive sera.
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unknown whether these antireceptor autoantibodies are just
a disease marker or whether they are disease causing,
although there is increasing evidence supporting that anti-
receptor autoantibodies may be involved in the pathogenesis
of idiopathic DCM (4,5).
Mechanisms responsible for the genesis of autoanti-
bodies. So far, there are only a few reports suggesting that
the production of anticardiac receptor autoantibodies might
be related to the virus-induced cardiac damage and cross-
reacting antigens (16,17). However, in our experimental
models, neither the virus infection nor the cross-reacting
antigens were involved. Nevertheless, the two models of
heart failure in the rat in this study are both associated with
myocyte necrosis and lysis, so we can assume that, in our
experiment, the cardiac myocyte necrosis and lysis, along
with structural and functional cardiac changes, may have
affected immunologic function, as evidenced by the imbal-
ance between the helper and cytotoxic T cells, and thus
resulted in the genesis of autoantibodies. Although the
trigger for autoantibody production may be myocyte necro-
sis (18), continued generation of autoantibodies may be
caused by triggering of the neuroendocrine axis (19).
Characteristic time course of the generation of auto-
antibodies. In this study, both types of autoantibodies
generated during the myocardial remodeling process
showed a characteristic self-growth and time-course decline.
Our observations demonstrated that the existence of both
autoantibodies lasted for only a short period, with the titers
gradually tapering in about two to three months. An
immunosuppressive effect due to a neurohormonal disorder,
occurring in the advanced stage of heart failure, may lead to
the disappearance of the antireceptor antibodies (20). The
regular growth and decline pattern of the autoantibodies
could account for the clinical observation that positive sera
for antireceptor autoantibodies are only detectable in a
subgroup of patients with DCM and other heart diseases
associated with heart failure. Although these autoantibodies
only exist for a short period during the whole cardiac
pathologic process, the antireceptor autoantibodies can
indeed be pathophysiologically important in the develop-
ment of heart diseases. Clinically speaking, therefore, the
negative findings of antireceptor autoantibodies in the sera
of patients with DCM or other heart diseases do not
necessarily imply that there is no autoimmune reaction
involved in the pathogenesis throughout the whole patho-
logic process. In concert with our findings, it was reported,
clinically, that autoantibodies against the adenine nucleotide
translocator exist in the sera of patients with DCM, only for
a short period of about two to three months (20). Moreover,
Caforio et al. (21) reported that cardiac autoantibodies in
patients with DCM become undetectable with disease
progression.
It is obvious that many gaps still remain in the current
knowledge of the occurrence of autoantibodies directed
against cardiac receptors, in relation to myocardial patho-
logic changes. Nevertheless, our preliminary observations
may open new insights into the mechanism that involves the
immunoreaction in the pathogenesis or pathologic role of
some heart diseases, and may be the starting point for future
new studies.
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